Esperion Therapeutics, Inc. (NASDAQ:ESPR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “

Several other brokerages have also weighed in on ESPR. BidaskClub lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 4th. Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 price target (up from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. Deutsche Bank AG set a $64.00 price target on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Jefferies Group LLC raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and decreased their target price for the company from $85.00 to $55.00 in a report on Tuesday, August 8th. Finally, UBS AG reissued a “buy” rating and issued a $57.00 target price (up from $52.00) on shares of Esperion Therapeutics in a report on Tuesday, June 27th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Esperion Therapeutics has a consensus rating of “Buy” and a consensus price target of $44.65.

Shares of Esperion Therapeutics (NASDAQ:ESPR) traded down 1.71% on Wednesday, hitting $43.80. The company’s stock had a trading volume of 363,114 shares. The company’s market cap is $989.57 million. The stock’s 50 day moving average is $47.22 and its 200-day moving average is $37.31. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $57.38.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by $0.25. During the same period last year, the business posted ($0.62) EPS. On average, equities research analysts anticipate that Esperion Therapeutics will post ($7.33) earnings per share for the current year.

WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/23/esperion-therapeutics-inc-espr-upgraded-by-zacks-investment-research-to-hold.html.

Several large investors have recently bought and sold shares of ESPR. Advisor Group Inc. increased its stake in Esperion Therapeutics by 0.6% in the third quarter. Advisor Group Inc. now owns 14,437 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 85 shares during the last quarter. US Bancorp DE increased its stake in Esperion Therapeutics by 1.1% in the second quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock worth $457,000 after buying an additional 104 shares during the last quarter. American International Group Inc. increased its stake in Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 584 shares during the last quarter. Voya Investment Management LLC increased its stake in Esperion Therapeutics by 12.7% in the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 806 shares during the last quarter. Finally, Nationwide Fund Advisors increased its stake in Esperion Therapeutics by 2.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company’s stock worth $1,387,000 after buying an additional 921 shares during the last quarter. Institutional investors own 85.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.